Startups
Eli Lilly is undertaking a strategic transformation that will result in the formation of new business units.
Check out where the money went in the life sciences industry this week.
Inflammation is an important protective mechanism if it can be controlled. This is a key component of Genti’s engineering and the secret to the potency of its Tregs.
Show me the money! This week’s who’s who of IPOs and financing rounds in the biopharma world.
Iterative Scopes closed on a $30 million Series A round. It was led by new investor Obvious Ventures, with participation from Eli Lilly, Johnson & Johnson Innovation – JJDC, Breyer Capital and Seae Ventures, in addition to Lee Shapiro, Zach Weinberg and Nat Turner.
The three companies will use their proceeds to support the development of their pipelines through additional business development opportunities.
Collaborating with Frazier Healthcare Partners, the team spun out a new company dubbed HilleVax to take Takeda’s norovirus vaccine into Phase 3 trials.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
Three companies, including two biotech companies and one drug discovery company, announced yesterday the successful closing of Series A financing, with IMIDomics taking the lead.
Biotech company Slingshot Biosciences announced Thursday it had closed a $23 million Series A financing round led by Northpond Ventures.
PRESS RELEASES